Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

A "fit and healthy" woman from Devon who survived an "incredibly rare" aortic dissection has said she is determined to make ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...

Patients who underwent transcatheter aortic valve replacement (TAVR ... The 30-day mortality rates were also lower in the continued access cohort (0.9%) compared to the initial premarket approval ...

Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the EvolutTM ...

It’s better to be told nothing is wrong than to regret not seeing a medical professional sooner. Here's what you need to know ...